Moreover, we concurrently demonstrated that RDD-142 decreased p-AKT levels in HCC in a dose-dependent manner [27], suggesting an involvement in the inhibition of the AKT signaling pathway. The gene discussed is AKT1; the disease is hepatocellular carcinoma.